This study used kill-kinetic methods to provide data on the bactericidal activity of subinhibitory (1/2x MIC), inhibitory (lx MIC), and suprainhibitory (4X, 6x, and 8x MIC) concentrations of deptomycin (LY146032) against strains of enterococci compared with those of ciprofloxacin, vancomycin, and ampicillin. Deptomycin was the most active agent tested, as determined by broth microdilution methods, with all strains being inhibited at concentrations <2 ,ug/ml. The kill-kinetic studies demonstrated that deptomycin had greater activity at aDl concentrations tested than the other cell wall-active agents; regrowth was seen, however, at lower concentrations. At higher concentrations (6x and 8x MIC), all aagents tested demonstrated the same or less bactericidal activity than at 4x MIC, presumably due to the Eagle effect. Nevertheless, these results suggest that further evaluation of deptomycin as a therapeutic agent for serious enterococcal infections is warranted.
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Deptomycin (LY146032) is a cyclic polypeptide which by standard broth dilution techniques has been shown to be bactericidal against enterococci at concentrations near the MIC (4, 6) . This suggests that deptomycin may be useful clinically as a single agent against serious enterococcal infections, including endocarditis. This study used killkinetic methods to provide data on the bactericidal activity of subinhibitory (1/2 x MIC), inhibitory (lx MIC), and suprainhibitory (4x, 6x, and 8x MIC) concentrations of deptomycin against strains of enterococci compared with those of ciprofloxacin, vancomycin, and ampicillin.
MATERIALS AND METHODS
Microorganisms. Ten clinical isolates of enterococci and Streptococcus faecalis ATCC 29212 were studied. These isolates were selected from more than 200 blood culture isolates of enterococci for which the MICs of vancomycin, ampicillin, and gentamicin had been determined previously.
Selection was done to provide a wide range of MICs of the three agents previously tested. Identification was performed by established methods (5) , which included the ability to grow in medium containing 40% bile, to hydrolyze esculin, and to grow in broth containing 6.5% sodium chloride. All strains were identified as S. faecalis.
Antimicrobial agents. Standard antimicrobial reference powders and their sources were as follows: deptomycin and vancomycin, Eli Lilly & Co., Indianapolis, Ind.; ciprofloxacin, Miles Pharmaceuticals, West Haven, Conn.; and ampicillin, Bristol Laboratories, Syracuse, N.Y. Antimicrobial agent stock solutions were prepared as specified by the manufacturers and stored at -70°C until use. Final concentrations were prepared on the day they were used.
Media. Mueller-Hinton broth (BBL Microbiology Systems, Cockeysville, Md.) was used in both the broth microdilution method and the kill-kinetic method. The broth was supplemented with physiologic concentrations of calcium and magnesium to achieve a final concentration of 50 mg of Ca2' and 25 mg of Mg2+ per liter of medium (16 (14) . For this method, 10-fold dilutions were made in physiologic saline, and a calibrated micropipetter was used to deliver five 0.05-ml portions from each dilution onto a sheep blood agar plate. These plates were incubated for 24 h, colonies were counted and averaged, and the final inoculum was calculated.
Broth microdilution method. This method was done by standard methods (16) with cation-supplemented MuellerHinton broth. Serial twofold dilutions (ranging from 0.0625 to 32 ,ug/ml) were prepared in broth and used to test each isolate. The final inoculum was 5 x 104 CFU per well and was confirmed each time by the modified surface colony count method as described above. A micropipetter that delivered 0.05 nil was used to inoculate each well of the microdilution plate (Dynatech Laboratories, Inc., Alexandria; Va). The final volume in each well was 0.1 ml. After 24 h of incubation at 35°C, the plates were removed and read with a microtiter mirror. The MIC was defined as the lowest concentration of the antimicrobial agent that inhibited growth of the test organism. MICs were determined in duplicate on at least two separate occasions. S. faecalis ATCC 29212 was used each time for quality assurance.
Kill-kinetic studies. Kill-kinetic studies were done in duplicate on separate occasions essentially as described by Krogstad and Moellering (8) and Chalkley and Koornhof (1) . All kill-kinetic studies were done with a final volume of 30 ml of broth in glass bottles. Borosilicate glass bottles without medium were kihdly supplied by Johnston Laboratories (Baltimore, Md.). Cation-supplemented Mueller-Hinton broth was used as the medium. Both the antimicrobial agent to be tested and the inoculum were added so as to maintain a final volume of 30 ml. The inoculum added was calculated to achieve a final concentration of 105 CFU/ml. Each isolate was tested in kill-kinetic studies to establish the effect of subinhibitory (1/2 x MIC), inhibitory (1 x MIC),' and suprainhibitory (4x, 6x, and 8 x MIC) concentrations of the aptibiotics. The concentration of each antimicrobial agent against each microorganism was determined by the MIC for that specific combi'nation. Bottles were incubated on a shaker (Johnston Laboratories, Baltimore, Md.) at 35°C for 24 h, which allowed growth in the control bottles to reach a level of 109 to 1010 CFU/ml. Comparisons of bottles which were shaken versus bottle which were not shaken demonstrated that the regrowth seen at lower concentrations did not result from organisms washed back into the broth after having escaped antibiotic exposure on the walls of the flask. Bottles were subcultured for colony counts at 0, 4, 8, 12, 16, 20 , and 24 h of incubation. Colony counts were performed by removing 0.5 ml of the broth with a syringe and making 10-1, 10-2, 10-3, and i0-dilutions in sterile physiologic saline. A 0.02-ml portion of each dilution was plated onto sheep blood agar plates and incubated for 24 h. The number of colonies was counted and used to determine the number of viable CFU at each sampling time. Kill-kinetic curves were then plotted showing time versus CFU per milliliter of broth. The mean percent inoculum killed by specific concentrations at various times was then determined. Each strain was studied at least twice for all antibiotics.
RESULTS
Broth microdilution method. The results of the broth microdilution susceptibility tests are shown in Table 1 . Deptomycin was the most active agent tested, with all strains being inhibited at concentrations of s2 ,ug/ml. Vancomycin and ciprofloxacin were quite active, inhibiting all strains at concentrations of s4 ,ug/ml.
Kill-kinetic studies. The bactericidal effect of each antibiotic at subinhibitory concentrations (1/2x MIC) was such that no agent killed even a tenth of the microorganism tested. Table 2 indicates the effect of each antibiotic at inhibitory killing of the initial inoculum. For isolates with higher MICs, the bactericidal effect most often was less than that of 4x MIC. The concentrations used for these isolates were usually higher than would be achieved clinically. DISCUSSION Enterococci rank as the third most common cause of endocarditis behind viridans group streptococci and Staphylococcus aureus. This pathogen is isolated from 10 to 15% of patients with endocarditis (10) (11) (12) 20) . Therapy for patients with enterococcal endocarditis is difficult because enterococci are tolerant to the bactericidal activity of cell wall-active agents such as ampicillin and vancomycin (7, 9) . In addition, aminoglycoside resistance is a potential problem (13) . Because optimal therapy for infective endocarditis depends on obtaining bactericidal activity in vivo (2, 22 ) the use of beta-lactam agents, vancomycin, or aminoglycosides alone is not feasible. Instead, combined therapy (a cell wall-active agent with an aminoglycoside) is routinely used for enterococcal endocarditis (17, 19, 20, 22) .
Deptomycin is a recently developed antibiotic (4, 6) which belongs to a novel class of acidic lipopeptide agents (3) . Deptomycin has demonstrated significant in vitro activity against enterococci, with bactericidal activity occurring near the MIC (4, 6). The antimicrobial properties of this new lipopeptide appear to result from its ability to inhibit cell wall peptidoglycan synthesis (N. Allen, W. Alborn, Jr., J. Hobbs, Jr., and H. Percifield, Program Abstr. 24th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 1081, 1984) . Because other cell wall-active agents, including penicillins and vancomycin, are only bacteriostatic against enterococci (9) , the bactericidal activity of deptomycin, a new member of the cell wall-active group of antibiotics, against enterococci became an important issue. Therefore, kill-kinetic studies were used to provide data on the bactericidal activity of subinhibitory ( deptomycin against strains of enterococci compared with those of ciprofloxacin, vancomycin, and ampicillin. Both cell wall-active agents (deptomycin, vancomycin, and ampicillin) and a non-cell-wall-active agent (ciprofloxacin) were included in this study. The in vitro activity of the acidic lipopeptide agents (including deptomycin) demonstrates a striking dependence on the calcium concentration in the growth medium (3, 4, 6) ; accordingly, cation-supplemented Mueller-Hinton broth was used for all susceptibility tests.
Deptomycin was the most active agent tested, as determiped by broth microdilution methods, with all strains being inhibited at concentrations of c2 ,uglml. Kill-kinetic studies demonstrated that deptomycin had greater activity at all concentrations tested than did the other cell wall-active agents tested; however, regrowth was frequently seen at lower concentrations. The bactericidal activity at 6x and 8 x MIC was less for isolates with higher MICs than the activity at 4 x MIC. Presumably, this is due to the Eagle effect. ICAAC, abstr. no. 338, 1984) . Finally, these data do not address the influence of human serum on the bactericidal activity of antimicrobial agents against enterococci. Storch and Krogstad (18) have shown that antibiotic-induced lysis of enterococci is markedly decreased in human serum. Nevertheless, there are sufficient data on the bactericidal activity of deptomycin, including that obtained from this study, to warrant further evaluation of this drug as a therapeutic agent for serious enterococcal infections, including endocarditis. The availability of an additional non-betalactam cell wall-active agent with rpasonable bactericidal activity against enterococci may become particularly important should beta-lactamase-producing strains (15) 
